Adria Pharmaceuticals

Known as: adria 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1965-2017
024619652017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1993
1993
PURPOSE The Sixth International Society of Pediatric Oncology study (SIOP6) concerned Wilms' tumor with favorable histology… (More)
Is this relevant?
1991
1991
Although previous studies have suggested a relatively poor prognosis for some patients with peripheral T-cell lymphoma, the… (More)
Is this relevant?
1991
1991
We designed an ex vivo bone marrow treatment for breast cancer patients receiving high-dose chemotherapy and autologous bone… (More)
Is this relevant?
Highly Cited
1990
Highly Cited
1990
While diffuse large-cell lymphoma (DLCL) is considered to be highly curable with current therapy, treatment failures are observed… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
  • figure 2
Is this relevant?
Highly Cited
1990
Highly Cited
1990
One hundred five untreated adult patients with acute lymphocytic leukemia (ALL) were entered on the vincristine, Adriamycin… (More)
Is this relevant?
1988
1988
Surgery alone is inadequate therapy for limited small-cell lung cancer (SCLC), resulting in less than 5% long-term survival… (More)
Is this relevant?
Highly Cited
1987
Highly Cited
1987
Natural killer (NK) cell activity and psychological status were measured at baseline and at 3 months into treatment, as part of… (More)
Is this relevant?
1986
1986
We report the largest series of induction chemotherapy for inflammatory breast carcinoma (IBC). Results of two chemotherapy… (More)
Is this relevant?
1986
1986
The Lung Cancer Study Group randomized 141 patients with resected stage II and III adenocarcinoma and large-cell undifferentiated… (More)
  • table 1
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
1985
Highly Cited
1985
After hysterectomy, 156 evaluable patients with stage I (limited to the corpus) or stage II (limited to the corpus and cervix… (More)
Is this relevant?